TargED doses first patient in TGD001 study for iTTP
TargED Biopharmaceuticals has dosed the first patient in a Phase 1/2 study of TGD001, a targeted clot-dissolving drug, in the rare blood disorder iTTP.
Stay updated on the latest breakthroughs, funding news, and success stories from the founders and researchers at Utrecht Science Park.
TargED Biopharmaceuticals has dosed the first patient in a Phase 1/2 study of TGD001, a targeted clot-dissolving drug, in the rare blood disorder iTTP.
Our fall Student Validation cohort kicked off on October 29. Meet the seven student startups testing their ideas with real customers over the next ten weeks.
Our fall Tech Validation cohort started on October 26. Meet the seven tech startups finding out whether their idea solves a real problem for real customers.
On November 2, researchers and doctors kicked off our Science Validation program. Meet the six startups finding out whether there's a path from lab to market for their work.
DUB spoke with three Utrecht University student entrepreneurs about hope and running a startup. Two of them, Ivo Zalesak (MicroDex) and Yeline Hoogmans (ASAP Safety), took part in our Student Validation Program.
Three UtrechtInc startups are competing in the Incubator Pitch Battle, and public voting is now open. Startups from incubators across the Netherlands have recorded their pitches.
Nestpod, alumni of our Tech Validation Program last year, now has a pod at Ramstein Air Base in Germany, its first placement outside the Netherlands.
UtrechtInc is looking for an entrepreneurial and connecting Managing Director. Are you an inspiring leader who spots opportunities and has the drive to act on them? Do you get your energy from bringing together science, government and business?
The programme includes practical insights on financing, founder experiences, and workshops led by financiers. Opening by Professor Edwin Weesie, with entrepreneur and alumni Madelon Bracke and Code-V rockstar Veronike Fikse.